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Purpose: We aimed to evaluate outcomes of the elderly (>65 years) by comparing with younger
(<40 years) patients after treatments for nasopharyngeal carcinoma (NPC).
Materials and methods: We retrospectively obtained clinical data from charts for 23 older and 21 younger
patients in whom NPC was diagnosed and who underwent curative managements during 2007 and 2011.
Occurrence of local recurrence, distant metastasis, and death from any cause were recorded as endpoints.
Cox proportional hazards regression was applied to determine age effects on survival risks after adjusting
for the potential confounders.
Results: Older patients more commonly received a diagnosis of chronic diseases than the younger
patients (56.5% versus 23.8%, p ¼ 0.036), whereas they were less likely to have received intensive
treatments for NPC. After adjusting for medical history and neoadjuvant chemotherapy, older age was
the only signiﬁcant predictor in the study cohort for overall survival and progression-free survival. The
adjusted hazard ratio (HR) for death from all causes in older patients was 6.3 (95% conﬁdence
interval [CI] ¼ 1.3e30.2), and the adjusted HR for disease progression in older patients was 10.9 (95%
CI ¼ 2.3e50.6).
Conclusion: Aging was the only independent prognostic risk factor in this study cohort. Medical history
and treatment variations could not fully explain the difference in prognosis. Our results strengthen the
need to ameliorate toxicities and improve supportive care for older patients with a diagnosis of NPC.
Copyright  2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Nasopharyngeal carcinoma (NPC) is common in Chinese de-
scendants in southeast Asia. The prevalence of NPC in Taiwan is 6.17
per 100,000, markedly higher than that (less than 1 per 100,000) in
Western countries1. The disease has been causally associated with
diet (e.g., smoked ﬁsh, nitrosamine), infection [e.g., Epstein-Barr
virus (EBV)], and genetic factors (e.g. HLA-A2)2. When compared
with other head and neck cancers, NPC is more radiosensitive and
yields better predictions of survival2. The mainstay of treatment ofs of interest to declare.
of Otolaryngology-Head and
-Shan North Road Section 2,
tric Emergency & Critical Care MeNPC is concomitant chemoradiotherapy (CCRT), whereas surgical
resection is recommended for local recurrence as a salvage strat-
egy3,4. According to the seventh edition of the American Joint
Committee on Cancer (AJCC) report, the 5-year rate was 81% for
overall survival, 90% for local relapse-free survival, 86% for distant
metastasis-free survival, and 77% for disease-free survival5.
As the population ages and experiences longer life expectancy,
diagnosis of NPC at an older age has become more frequent.
Treatment and management of the condition in elderly patients is
now a pressing task. Several concerns arise when the diagnosis is
made at an older age, including tolerance to CCRT versus radio-
therapy alone. Management pattern, staging, and comorbidities
have been empirically correlated with an increasing age and poor
prognosis in patients with NPC6. The objective of this retrospective
study was to evaluate the effect of age on the outcomes of NPC
patients with NPC while taking these factors into account.dicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographic and diagnostic characteristics of nasopharyngeal cancer patients by
age group.
Age <40 y
N ¼ 21
Age >65 y
N ¼ 23
pa
Age 33 (26e39) 70 (66e81)
Sex
Female 4 (19.0) 9 (39.1) 0.194
Male 17 (81.0) 14 (60.9)
Comorbidityb
None 16 (76.2) 10 (43.5) 0.036
Any 5 (23.8) 13 (56.5)
Clinical T
1e2 14 (66.7) 12 (52.2) 0.373
3e4 7 (33.3) 11 (47.8)
Clinical N
0e1 7 (33.3) 11 (47.8) 0.373
2e3 14 (66.7) 12 (52.2)
Stage
IeII 7 (33.3) 7 (30.4) 0.351
IIIeIVB 12 (57.2) 16 (69.6)
IV C 2 (9.5) 0
Baseline EBV VCA-IgA 3.1 (0.6e9.7) 2.3 (0.6e7.0) 0.239c
Baseline EBV EA þ NA1 IgA 34.4 (2.2e242) 49.9 (2.4e137.3) 0.735c
Data are presented as n (%) or median (range).
EA ¼ early antigen; EBV ¼ Epstein-Barr virus; IgA ¼ immunoglobulin A; NA ¼
nuclear antigen; VCA ¼ viral capsid antigen.
a Fisher’s exact test.
b Medical history of cancers, diabetes, cardiovascular diseases, or hypertension.
c Mann-Whitney U test.
Table 2
Treatment courses and clinical outcomes by age group.
Age <40 y
N ¼ 21
Age >65 y
N ¼ 23
pa
NACT
No 4 (19.1) 11 (47.8) 0.060
Yes 17 (80.9) 12 (52.2)
Deﬁnitive treatmentb
Radiotherapy only 0 11 (47.8) <0.001
CCRT 19 12 (52.2)
Adjuvant
No 5 (23.8) 17 (73.9) 0.002
Yes 16 (76.2) 6 (26.1)
Response to treatment
CR 18 (85.7) 18 (78.3) 0.416
PR 2 (9.5) 5 (21.7)
No response 1 (4.8) 0
EBV VCA-IgA 1 y after treatment 4.2 (1.0e6.5) 4.7 (0.9e8.5) 0.659c
EBV EA þ NA1 IgA 1 y
after treatment
22.0 (2.6e128.0) 62.3 (0.2e128.0) 0.631c
Disease status during follow-up
Remained CR or PR 18 (85.7) 14 (60.9) 0.135
Second primary malignancy 0 1 (4.4)
Recurrence 0 4 (17.4)
Metastasis 3 (14.3) 4 (17.4)
Data are presented as n (%) or median (range).
CCRT ¼ concurrent chemoradiotherapy; CR ¼ complete response; EBV ¼ Epstein-
Barr virus; IgA ¼ immunoglobulin A; NACT ¼ neoadjuvant chemotherapy;
PR ¼ partial response; VCA ¼ viral capsid antigen.
a Fisher’s exact test.
b Two younger and one older patient receiving target therapy concurrent with
radiotherapy were excluded from the analysis.
c Mann-Whitney U test.
Y.-S. Leu et al.822. Materials and methods
The study included patients in whom NPC had been diagnosed
at age older than 65 years or younger than 40 years, and who un-
derwent curative therapies between January 2007 and December
2011 in the Mackay Memorial Hospital, Taipei, Taiwan. Twenty-
three older patients and 21 younger patients fulﬁlled the criteria.
We retrospectively conducted a detailed chart review to obtain
information on medical history, treatment, and clinical outcomes.
TNM stage was determined based on the AJCC Staging Manual,
sixth edition. Management strategy was discussed within a multi-
disciplinary team and with the patient soon after the diagnosis.
Most of the patients received CCRT. Only 11 older patients received
radiotherapy alone for poor condition (N ¼ 7) or stage I/II (N ¼ 4).
During CCRT, a total of 57.6-70 Gy was delivered in 32e35 equal
fractions, ﬁve daily fractions per week.Weekly cisplatin (30mg/m2)
or monthly 5-day course of cisplatin (12 mg/m2) and ﬂuorouracil
(600 mg/m2) were prescribed concurrently with radiotherapy.
Neoadjuvant chemotherapy (NACT) prior to radiotherapy was
composed of cisplatin (75mg/m2) and ﬂuorouracil (2600mg/m2) in
2 days (PF2). Two to four courses of PF2 were administered as
adjuvant chemotherapy for advanced cases with acceptable per-
formance. This study was approved by the Institutional Review
Board of the Mackay Memorial Hospital (No.12MMHIS109).
2.1. Statistical analysis
Differences in diagnostic and treatment characteristics between
the old and young groups of patients were evaluated by Fisher exact
test and Mann-Whitney U test. Information on medical history of
other cancers, benign tumors, cardiovascular diseases, hyperten-
sion, diabetes, tuberculosis, and chronic hepatitis was extracted
from charts as the comorbidities. Among these conditions, only
other history of cancers, diabetes, cardiovascular diseases, and hy-
pertension showed a mild to signiﬁcant association with age at
diagnosis, and were included in the following analyses. Occurrence
of local recurrence, distant metastasis, and death from any cause
were recorded as the endpoints in the present study. Cumulative
survival rates from the day of diagnosis to the endpoints were
computerized using the Kaplan-Meier survival analysis. Cox pro-
portional hazards regressionwas also applied to evaluate the effect
of age on survival risks after adjusting for the potential con-
founders. Hazard ratios (HR) and 95% conﬁdence intervals (95% CI)
were estimated with signiﬁcance level set at 0.05 for all the two-
sided tests.
3. Results
The median duration of follow-up was 25.8 months for older
patients (range, 2.8e66.2 months) and 32.7 months for younger
patients (range 8.6e68.3 months, p ¼ 0.307, data not shown).
Medical history, including cancers, diabetes, cardiovascular dis-
eases, and hypertension, was signiﬁcantly more prevalent in the
older group than in the younger group (56.5% in older patients vs.
23.8% in younger patients, p ¼ 0.036, Table 1). There was no dif-
ference in clinical stage and baseline EBV titers between the age
groups.
Treatment history and clinical response are summarized in
Table 2. Fewer older patients received NACT (52.2%), CCRT (52.2%),
and adjuvant chemotherapy (26.1%) than their younger counter-
parts (80.9% for NACT, 100% for CCRT, and 76.2% for adjuvant
chemotherapy, Table 2). All of the older patients initially responded
to treatment, achieving complete response (CR) in 78.3% and partial
response (PR) in 21.7%, but more than a third of the older patients
developed second primary malignancy, locoregional recurrence, ordistant metastasis later during follow-up (Table 2). Three younger
patients (14.3%) had distant metastasis, and 85.7% of the younger
patients remained CR or PR during follow up.
Five-year overall survival (OS) was 45.3% in older patients
(median 41.4 months), relative to 88.8% in younger patients (me-
dian not reached, p ¼ 0.015). We also observed signiﬁcantly higher
risk of disease progression or death for older patients (5-year
progression-free survival, PFS, 18.7%, median 32.2 months) when
Fig. 1. Kaplan-Meier survival analysis for patients with nasopharyngeal cancer by age group. (A) Overall survival. (B) Progression-free survival. (C) Local recurrence-free survival. (D)
Distant metastasis-free survival.
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reached, p¼ 0.002). The 5-year local recurrence free survival (LRFS)
and distant metastasis free survival (DMFS) were 49.2% and 78.8%
in the older patients, respectively. The estimates tended to favor
younger patients (5-year LRFS 90.0% and DMFS 81.4%), but the
difference was not statistically signiﬁcant (Fig. 1C and D).
After adjusting for medical history and neoadjuvant chemo-
therapy, age older than 65 years was the only signiﬁcant predictor
in the study cohort for OS and PFS. The adjusted HR for death from
all causes in older patients was 6.3 (95% CI ¼ 1.3e30.2), and the
adjusted HR for disease progression in elder patients was 10.9 (95%
CI¼ 2.3e50.6, Table 3). Adding CCRTand adjuvant chemotherapy to
the multivariate model did not signiﬁcantly change the results.Table 3
Cox proportional hazard models for prognostic factors in patients with nasopha-
ryngeal cancer by age group.
Death Disease
progression
Local
recurrence
Distant
metastasis
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Crude
age (y)
<40 1.0 1.0 1.0 1.0
>65 5.4 (1.2e24.7) 8.8 (2.0e39.1) 2.5 (0.5e14.0) 1.4 (0.3e6.1)
Adjusted
age (y)
<40 1.0 1.0 1.0 1.0
>65 6.3 (1.3e30.2) 10.9 (2.3e50.6) 3.2 (0.5e20.1) 1.6 (0.3e8.4)
Comorbidity
None 1.0 1.0 1.0 1.0
Any 0.6 (0.3e1.2) 0.8 (0.4e1.3) 0.6 (0.2e1.9) 0.7 (0.2e2.0)
Neoadjuvant
No 1.0 1.0 1.0 1.0
Yes 0.5 (0.1e1.5) 1.1 (0.4e3.2) 0.7 (0.1e3.8) 0.7 (0.1e3.3)
CI ¼ conﬁdence interval; HR ¼ hazard ratio.Adjusted HR was 31.0 (95% CI 3.2e302.1) for disease progression in
older patients.
4. Discussion
Despite a decrease in overall cancer death rates, the increase in
the elderly population is expected to increase the burden of cancer
in the United States7. Therefore, it is important to recognize age-
speciﬁc differences in common cancer8. The purpose of this study
was to compare the outcomes between elderly and younger pa-
tients with NPC, after controlling for comorbidity and treatment.
Our data suggested age is an independent prognostic factor.
Many older patients refuse intensive treatments because they
fear the adverse effects might not be bearable in addition to the
existing comorbidities. More often than not, there are also concerns
about family and ﬁnancial supports during the process of medical
care. Results of this study conﬁrmed that older patients are less
likely to receive NACT (52.2% in older patients vs. 81.0% in younger
patients), CCRT (52.2% in older patients vs. 100.0% in younger pa-
tients), and adjuvant chemotherapy (26.1% in older patients vs.
76.2% in younger patients) regardless of clinical stage. Although
aging may induce poor performance and aggressive treatment-
related toxicities, all of the older patients initially achieved CR or
PR to the treatments with curative intent. Long-term survival may
be inﬂuenced by the compromised treatments in the elderly. Pro-
longed beneﬁt in OS and DFSmight be plausible for older patients if
they are encouraged to complete the treatments with carefully
adjusted drug doses.
Nonetheless, effectiveness and tolerability of chemotherapy and
radiotherapy remain critical controversy for older patients with
malignancy. Several retrospective oncologic studies reported no
increased toxicity in the elderly, during treatments against breast
cancer9, colon cancer10, or cervical cancer11, whereas other
studies12e15 observed older patients sufferedmore from treatment-
related complications. Intensity of the treatments may help to
Y.-S. Leu et al.84explain the difference in tolerance for elderly, and consequently
alter the outcome. Vercelli et al12 found worse prognosis following
the increased toxicities for elder cancer patients in a European trial.
However, older age at diagnosis was a predictor of worse survival in
patients with head and neck cancer13 but also a favorable factor in
survivals for breast cancer14 and esophageal cancer15.
In addition to the concerns of tolerance, older age has been
associated with metabolic changes, higher incidence of comorbid-
ities, and polypharmacia16. These conditions potentially increase
treatment-related complications17. Acute treatment-related toxic-
ities, such as neutropenia and gastrointestinal symptoms, commonly
occur with chemotherapy and radiotherapy, but the symptoms are
transient and patients spontaneously recover with proper nutrition
support. In the current study, we observed more comorbidities in
older patients than younger patients. History of malignancies, hy-
pertension, diabetes, and cardiovascular diseases were signiﬁcantly
more prevalent in older patients, taking on possible competing
causes of death. These conditions may also compromise the admin-
istration of treatments for NPC. Therefore, it is important to closely
monitor the condition of older patients during treatment.
We observed a signiﬁcantly higher risk of death from all causes
and disease progression in older patients when compared to
younger ones after controlling for medical history and treatment-
related factors. Aging is the only prognostic factor signiﬁcantly
associated with the outcomes in the study cohort, and the differ-
ence in survival could not be simply explained away by diagnosis
of comorbidities or treatment intensity. We believe the results
underline both risks and beneﬁts for older patients when
compared to younger patients diagnosed with NPC. Such infor-
mation is essential for physicians and patients during the
decision-making process.
Because of the relatively low incidence of NPC in the elderly, we
conducted a retrospective caseecase comparison with information
on medical history, treatment responses, and survival outcomes
extracted from charts. The study design may introduce bias un-
known to the authors, and brought limitations such as missing data
on laboratory examinations. However, the study highlights the
need to carefully adjust the treatment strategies, and to ameliorate
the treatment-related toxicities for elder patients with NPC. Prog-
nosis may be improved with CCRT and other intensive medical care
for elderly as it is for younger patients.References
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